We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Romozosumab met its primary endpoint by minimizing new vertebral fractures in postmenopausal women with osteoporosis through months 12 and 24. Read More
French drug giant Sanofi will terminate its licensing agreement with Auvi-Q developer kaléo later this year, returning U.S. and Canadian rights to the epinephrine injection to the company. Read More